European medicines agencys CHMP recommends approval of Merck's KEYTRUDA® (Pembrolizumab) for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma

27th March 2017 Uncategorised 0

Merck

More: European medicines agencys CHMP recommends approval of Merck's KEYTRUDA® (Pembrolizumab) for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma
Source: MDlinx